Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits

por Berrington de González, A, Reeves, G
Publicado 2005

Oncofoetal fibronectin – a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma

por Hesse, E, Musholt, P B, Potter, E, Petrich, T, Wehmeier, M, von Wasielewski, R, Lichtinghagen, R, Musholt, T J
Publicado 2005

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease

por Berruti, A, Tucci, M, Mosca, A, Tarabuzzi, R, Gorzegno, G, Terrone, C, Vana, F, Lamanna, G, Tampellini, M, Porpiglia, F, Angeli, A, Scarpa, R M, Dogliotti, L
Publicado 2005

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

por Hasan, J, Ton, N, Mullamitha, S, Clamp, A, McNeilly, A, Marshall, E, Jayson, G C
Publicado 2005

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter random...

por Georgoulias, V, Agelidou, A, Syrigos, K, Rapti, A, Agelidou, M, Nikolakopoulos, J, Polyzos, A, Athanasiadis, A, Tselepatiotis, E, Androulakis, N, Kalbakis, K, Samonis, G, Mavroudis, D
Publicado 2005

The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area

por Piketty, A-C, Fléchon, A, Laplanche, A, Nouyrigat, E, Droz, J-P, Théodore, C, Fizazi, K
Publicado 2005

Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway

por Lewis, N R, Le Jeune, I, Baldwin, D R
Publicado 2005

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

por Jonasch, E, Wood, C, Tamboli, P, Pagliaro, L C, Tu, S M, Kim, J, Srivastava, P, Perez, C, Isakov, L, Tannir, N
Publicado 2008

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

por Antoniou, A C, Cunningham, A P, Peto, J, Evans, D G, Lalloo, F, Narod, S A, Risch, H A, Eyfjord, J E, Hopper, J L, Southey, M C, Olsson, H, Johannsson, O, Borg, A, Passini, B, Radice, P, Manoukian, S, Eccles, D M, Tang, N, Olah, E, Anton-Culver, H, Warner, E, Lubinski, J, Gronwald, J, Gorski, B, Tryggvadottir, L, Syrjakoski, K, Kallioniemi, O-P, Eerola, H, Nevanlinna, H, Pharoah, P D P, Easton, D F
Publicado 2008

Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis

por Gorouhi, F, Islami, F, Bahrami, H, Kamangar, F
Publicado 2008

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

por Mascaux, C, Iannino, N, Martin, B, Paesmans, M, Berghmans, T, Dusart, M, Haller, A, Lothaire, P, Meert, A-P, Noel, S, Lafitte, J-J, Sculier, J-P
Publicado 2005

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer

por Kim, S T, Kang, W K, Kang, J H, Park, K W, Lee, J, Lee, S-H, Park, J O, Kim, K, Kim, W S, Jung, C W, Park, Y S, Im, Y-H, Park, K
Publicado 2005

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

por Serin, D, Verrill, M, Jones, A, Delozier, T, Coleman, R, Kreuser, E-D, Mross, K, Longerey, B, Brandely, M
Publicado 2005

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric c...

por Moehler, M, Eimermacher, A, Siebler, J, Höhler, T, Wein, A, Menges, M, Flieger, D, Junginger, T, Geer, T, Gracien, E, Galle, P R, Heike, M
Publicado 2005

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)

por Dearnaley, D P, Fossa, S D, Kaye, S B, Cullen, M H, Harland, S J, Sokal, M P J, Graham, J D, Roberts, J T, Mead, G M, Williams, M V, Cook, P A, Stenning, S P
Publicado 2005

Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer

por Gowardhan, B, Douglas, D A, Mathers, M E, McKie, A B, McCracken, S R C, Robson, C N, Leung, H Y
Publicado 2005

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study

por Ardavanis, A, Tryfonopoulos, D, Alexopoulos, A, Kandylis, C, Lainakis, G, Rigatos, G
Publicado 2005

Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for ris...

por Jernström, H, Sandberg, T, Bågeman, E, Borg, Å, Olsson, H
Publicado 2005

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial...

por Atzpodien, J, Schmitt, E, Gertenbach, U, Fornara, P, Heynemann, H, Maskow, A, Ecke, M, Wöltjen, H H, Jentsch, H, Wieland, W, Wandert, T, Reitz, M
Publicado 2005

Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer

por Yeh, K H, Lu, Y S, Hsu, C H, Lin, J F, Chao, H J, Huang, T C, Chung, C Y, Chang, C S, Yang, C H, Cheng, A L
Publicado 2005